Status:

RECRUITING

Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome

Lead Sponsor:

Radboud University Medical Center

Collaborating Sponsors:

UMC Utrecht

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions:

Colorectal Cancer

Chemotherapeutic Toxicity

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Evidence from randomized controlled trials shows that exercise during cancer treatment benefits physical fitness, fatigue and quality of life. Since the effect of exercise on clinical outcome is curre...

Detailed Description

First-line treatment of metastatic colorectal cancer (mCRC) generally includes the chemotherapies fluoropyrimidines in combination with oxaliplatin and/or irinotecan, known as doublet or triplet chemo...

Eligibility Criteria

Inclusion

  • mCRC with indication for palliative chemotherapy
  • scheduled for treatment with first-line doublet or triplet chemotherapy, according to the national guideline
  • able and willing to give written informed consent.

Exclusion

  • life expectancy \<6 months
  • unable to perform basic activities of daily living such as walking or biking
  • presence of cognitive disorders or severe emotional instability (e.g., Schizophrenia, Alzheimer, alcohol addiction);
  • presence of other disabling co-morbidities that might hamper physical exercise (e.g. heart failure (NYHA classes 3 and 4), chronic obstructive pulmonary disease (COPD, gold 3 and 4), orthopaedic conditions and neurological disorders (e.g., hernia, paresis, amputation, active rheumatoid arthritis);
  • insufficient mastery of the Dutch language;
  • presence of serious cardiovascular or cardiopulmonary conditions (e.g. unstable angina, arrhythmia or valve disease) such that exercise safety is at risk, as judged by the treating physician.
  • Already participating in structured vigorous aerobic and/or resistance exercise ≥ 2 times per week comparable to our intervention

Key Trial Info

Start Date :

March 2 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

228 Patients enrolled

Trial Details

Trial ID

NCT04754672

Start Date

March 2 2021

End Date

December 1 2026

Last Update

November 18 2023

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands, 5223 GZ

2

Flevoziekenhuis

Almere Stad, Netherlands, 1315 RA

3

Meander Medisch Centrum

Amersfoort, Netherlands, 3813TZ

4

Ziekenhuis Amstelland

Amstelveen, Netherlands, 1186AM